Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson & Johnson / Janssen Biotech / Janssen-Cilag / AstraZeneca) and Xtandi (Pfizer / Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). Several current and emerging therapies are also being positioned in the lucrative nonmetastatic CRPC and metastatic hormone-sensitive settings. The late-phase pipeline for mCRPC has also become more dynamic, with two PARP inhibitors (Johnson & Johnson’s Zejula and Pfizer’s Talzenna), four immune checkpoint inhibitors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, Bristol-Myers Squibb/Ono Pharmaceutical’s Yervoy, Merck Sharp and Dohme’s Keytruda, and Roche/Genentech/Chugai’s Tecentriq), two kinase inhibitors (Array BioPharma / Roche / Genentech / Chugai’s ipatasertib and AstraZeneca’s capivasertib), one radioligand therapy (Novartis’ 177Lu-PSMA-617), and one angiogenesis inhibitor (Exelixis / Takeda / Ipsen’s Cabometyx) in Phase III development.
- What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
- How is prostate cancer currently managed, and how will treatment practices change in the future?
- What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2028?
- What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.
Key companies: Johnson & Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Bayer HealthCare, Clovis Oncology, Merck Sharp & Dohme, Exelixis, Ipsen, Takeda.
Key drugs: Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Nubeqa (darolutamide), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Tecentriq (atezolizumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Cabometyx (cabozantinib), ipatasertib, relugolix, 177Lu-PSMA-617, capivasertib.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Carolina do Pazo, M.Sc; Narendra Parihar
Carolina do Pazo, M.Sc., is a Business Insights Analyst in the oncology division at Decision Resources Group. Prior to joining DRG, she completed a MSc in Biotechnology, Bioprocessing and Business Management with distinction at the University of Warwick, as a Chevening scholar. She also earned her first-class BSc and BEng in Biotechnology from the Universidad ORT. Ms. do Pazo has worked as a Research Scientist at the Institut Pasteur de Montevideo, analysing the ageing process of yeast cells, and has been part of a project between Indiana University and Universidad ORT that analysed the production of nanohybrids for drug delivery systems applications.
Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.